Genmab A/S (GMAB) Competitors

Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and profitability.

Which has more risk and volatility, GMAB or TAK?

Genmab A/S has a beta of 0.94, meaning that its share price is 6% less volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.23, meaning that its share price is 77% less volatile than the S&P 500.

Do analysts rate GMAB or TAK?

Genmab A/S presently has a consensus price target of $37.60, indicating a potential upside of 84.22%. Given Genmab A/S's higher probable upside, equities research analysts clearly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.67
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is GMAB or TAK more profitable?

Genmab A/S has a net margin of 35.11% compared to Takeda Pharmaceutical's net margin of 2.36%. Genmab A/S's return on equity of 18.08% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	35.11%	18.08%	14.52%
Takeda Pharmaceutical	2.36%	10.64%	5.14%

Do insiders and institutionals hold more shares of GMAB or TAK?

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Which has higher valuation and earnings, GMAB or TAK?

Genmab A/S has higher earnings, but lower revenue than Takeda Pharmaceutical. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.12B	4.19	$1.14B	$1.76	11.60
Takeda Pharmaceutical	$30.09B	1.64	$712.33M	$0.22	70.68

Does the media refer more to GMAB or TAK?

In the previous week, Genmab A/S had 1 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 3 mentions for Genmab A/S and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 0.94 beat Genmab A/S's score of 0.58 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Genmab A/S beats Takeda Pharmaceutical on 12 of the 17 factors compared between the two stocks.